Hanson Pharmaceuticals (03692) signs licensing agreement with GLENMARK for amitinib

Zhitongcaijing · 1d ago

According to Zhitong Financial App, Hanson Pharmaceuticals (03692) announced that on December 16, 2025, Jiangsu Hausen Pharmaceutical Group Co., Ltd. (licensor), a wholly-owned subsidiary of the company, entered into an exclusive licensing, cooperation and distribution agreement (license agreement) with Glenmark Specialty S.A. (licensee) for ametinib. Ametinib is a triple-representative dermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC).

Under the license agreement, the licensor will grant the licensee an exclusive license to develop and commercialize ametinib in the authorized regions (Middle East and Africa, Southeast Asia and South Asia, Australia, New Zealand, Russia and other CIS countries, and select Caribbean countries covered by the agreement). The licensor will receive a down payment and subsequent regulatory and commercial milestone payments that may accrue more than a billion dollars, as well as tiered royalties for net sales within the authorized region.